NDAINTRAMUSCULARSOLUTIONPriority Review
Approved
May 1973
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
7
Data completeness
4/8 — Partial
Priority Review
ATROPEN (atropine) by Medcaptain Medical Technology is cholinergic antagonists [moa]. First approved in 1973.
Drug data last refreshed Yesterday
Mechanism of Action
Cholinergic Antagonists
Pharmacologic Class:
Anticholinergic
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (7)
Atropine Eyedrops for Myopia Progression in Children and Adolescents (MODERATO STUDY)
Started Sep 2025
234 enrolled
Myopia
Treating Intraoperative Bradycardia in Non-cardiac Surgery Patients With Atropine at Heart Rates Below 60 Versus 30 Beats Per Minute and Norepinephrine Requirements
Started Apr 2025
186 enrolled
Intraoperative Bradycardia
Electronic Spectacles Versus Low Dose Atropine in Young Myopes
Started Oct 2023
45 enrolled
Myopia
A Study of Atropine Sulfate in Healthy Chinese Volunteers
Started May 2023
30 enrolled
Pharmacokinetics
A Phase III Clinical Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye Drops
Started May 2022
526 enrolled
Myopia
Worked on ATROPEN at Medcaptain Medical Technology? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.